AbbVie Collaborates with Caraway to Develop TMEM175 for Parkinson's Disease and Other Related Disorders
Shots:
- Caraway to receive ~$267M including $17M up front in cash and remaining as option payment & milestones and is eligible for additional regulatory and commercial milestones along with royalties & gets the option to take part in product development in exchange for higher royalty rates
- Post pre-clinical research and development activities- AbbVie has an option to license the program and proceed with IND-enabling studies- clinical development- and commercialization
- The collaboration leverages Caraway’s drug discovery platform- expertise in lysosomal biology & cellular clearance mechanisms combine with AbbVie’s expertise in disease biology- clinical development- and global commercialization
Ref: Business Wire | Image: Business Wire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com